ArticleJournal of neuro-oncology1994
p53 immunoreactivity in oligodendrogliomas.
Article in Journal of neuro-oncology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunohistochemical markers for prognosis of oligodendroglial neoplasms.Journal of neuro-oncology · 2002Article
- Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.Journal of neuro-oncology · 2002Article
- Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.Journal of neuro-oncology · 2001Article
- The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.Journal of neuro-oncology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data are presented on p53 protein presence in human oligodendrogliomas whose progress from low grade to anaplastic oligodendroglioma can be followed. Expression was evaluated by formalin-fixed paraffin-embedded section immunohistochemistry, using monoclonal PAb 1801 antibody. The frequency of p53 protein accumulation is related to the stage of tumor malignancy. All the samples (100%) of malignant oligodendrogliomas were positive for p53 protein. Of 14 type II oligodendroglioma samples, 9 were positive (64%) while among type I oligodendroglioma the positivity was 28%. The mean proportion of reactive cells was also higher in malignant oligodendrogliomas. However, mean intensity staining did not differ among various grades of tumors. Our results point to the direct link between p53 protein accumulation and the malignant stage of human oligodendrogliomas. However, the value of p53 protein accumulation in predicting malignant behavior of oligodendrogliomas requires further confirmation.
Indexed as
Identifiers
7714546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.